Trial Profile
Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance: A Pilot Study in Diffuse Large B-Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 20 Jun 2023 Planned End Date changed from 15 Dec 2023 to 15 Dec 2024.
- 20 Jun 2023 Planned primary completion date changed from 15 May 2023 to 15 May 2024.
- 03 Jan 2023 Planned primary completion date changed from 15 Dec 2022 to 15 May 2023.